Nextrials, Inc. will again participate in the annual IHE North America Connectathon sponsored by IHE (Integrating the Healthcare Enterprise), to be held January 9-14 at the Hyatt Regency Chicago. This is the fourth consecutive year for Nextrials’ participation in the event, where it will showcase the flexibility of Prism®, its clinical trial management platform; Prism is one of the clinical research industry’s few electronic data capture (EDC) platforms fully integrated with platforms used for electronic health records (EHR) by the healthcare industry. During the Connectathon demonstration on Saturday, January 14, Prism will facilitate live data streaming between multiple EHR vendors and data recipients.
Nextrials is one of just two EDC solution providers participating in the Connectathon, the healthcare IT industry’s only large-scale interoperability testing event dedicated to establishing standards that address specific clinical needs in support of optimal patient care. The event is an important qualifier for the HIMSS12 Interoperability Showcase™, being held at the Venetian-Sands Expo Convention Center in Las Vegas February 20-24, 2012.
Nextrials’ Prism melds clinical trial management functionality with EDC in a single, integrated package. By receiving a constant flow of data, Prism enables sponsors and sites to fully utilize real-time integration of disparate information and data sources, such as a hospital’s EHR or patient records, to better provide a continuum of care for patients enrolled in clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.